Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma

Xiaoxiang Chen; Jing Zhang; Zhihong Zhang; Hongxia Li; Wenjun Cheng; Jinsong Liu

doi:10.1016/j.humpath.2013.05.001

Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma

Xiaoxiang Chen, Jing Zhang, Zhihong Zhang, Hongxia Li, Wenjun Cheng, Jinsong Liu

Pathology

Research output: Contribution to journal › Review article › peer-review

55 Scopus citations

Abstract

Although epithelial ovarian cancer cells are eliminated by debulking surgery and chemotherapy during initial treatment, it is believed that only a subset of cancer cells, that is, cancer stem cells, may be an important source of tumor recurrence and drug resistance. This review highlights our current understanding of high-grade serous carcinoma, ovarian cancer stem cells, common methods for enrichment of ovarian cancer stem cells, mechanisms involved in drug resistance, and potential strategies for overcoming drug resistance, with associated potential controversies and pitfalls. We also review the potential relationship between epithelial-to-mesenchymal transition and cancer stem cells and how we can induce cancer cells to differentiate into benign stromal fibroblasts in response to certain chemotherapy drugs.

Original language	English (US)
Pages (from-to)	2373-2384
Number of pages	12
Journal	Human Pathology
Volume	44
Issue number	11
DOIs	https://doi.org/10.1016/j.humpath.2013.05.001
State	Published - Nov 2013

Keywords

Cancer stem cell
Epithelial-mesenchymal transition
High-grade ovarian serous cancer

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1016/j.humpath.2013.05.001

Cite this

@article{9e988443c0fe4c8cafe3713d22f4be02,

title = "Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma",

abstract = "Although epithelial ovarian cancer cells are eliminated by debulking surgery and chemotherapy during initial treatment, it is believed that only a subset of cancer cells, that is, cancer stem cells, may be an important source of tumor recurrence and drug resistance. This review highlights our current understanding of high-grade serous carcinoma, ovarian cancer stem cells, common methods for enrichment of ovarian cancer stem cells, mechanisms involved in drug resistance, and potential strategies for overcoming drug resistance, with associated potential controversies and pitfalls. We also review the potential relationship between epithelial-to-mesenchymal transition and cancer stem cells and how we can induce cancer cells to differentiate into benign stromal fibroblasts in response to certain chemotherapy drugs.",

keywords = "Cancer stem cell, Epithelial-mesenchymal transition, High-grade ovarian serous cancer",

author = "Xiaoxiang Chen and Jing Zhang and Zhihong Zhang and Hongxia Li and Wenjun Cheng and Jinsong Liu",

note = "Funding Information: Funding disclosure: J.L. was supported by an R01 grant ( CA131183-01A2 ) and an ovarian cancer Specialized Programs of Research Excellence (SPORE) grant ( IP50 CA83638 ) from the National Institutes of Health , the Ovarian Cancer Research Fund , and the National Foundation for Cancer Research . This work was also supported, in part, by the National Institutes of Health through MD Anderson{\textquoteright}s Cancer Center Support Grant ( CA016672 ). ",

year = "2013",

month = nov,

doi = "10.1016/j.humpath.2013.05.001",

language = "English (US)",

volume = "44",

pages = "2373--2384",

journal = "Human Pathology",

issn = "0046-8177",

publisher = "W.B. Saunders Ltd",

number = "11",

}

TY - JOUR

T1 - Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma

AU - Chen, Xiaoxiang

AU - Zhang, Jing

AU - Zhang, Zhihong

AU - Li, Hongxia

AU - Cheng, Wenjun

AU - Liu, Jinsong

N1 - Funding Information: Funding disclosure: J.L. was supported by an R01 grant ( CA131183-01A2 ) and an ovarian cancer Specialized Programs of Research Excellence (SPORE) grant ( IP50 CA83638 ) from the National Institutes of Health , the Ovarian Cancer Research Fund , and the National Foundation for Cancer Research . This work was also supported, in part, by the National Institutes of Health through MD Anderson’s Cancer Center Support Grant ( CA016672 ).

PY - 2013/11

Y1 - 2013/11

N2 - Although epithelial ovarian cancer cells are eliminated by debulking surgery and chemotherapy during initial treatment, it is believed that only a subset of cancer cells, that is, cancer stem cells, may be an important source of tumor recurrence and drug resistance. This review highlights our current understanding of high-grade serous carcinoma, ovarian cancer stem cells, common methods for enrichment of ovarian cancer stem cells, mechanisms involved in drug resistance, and potential strategies for overcoming drug resistance, with associated potential controversies and pitfalls. We also review the potential relationship between epithelial-to-mesenchymal transition and cancer stem cells and how we can induce cancer cells to differentiate into benign stromal fibroblasts in response to certain chemotherapy drugs.

AB - Although epithelial ovarian cancer cells are eliminated by debulking surgery and chemotherapy during initial treatment, it is believed that only a subset of cancer cells, that is, cancer stem cells, may be an important source of tumor recurrence and drug resistance. This review highlights our current understanding of high-grade serous carcinoma, ovarian cancer stem cells, common methods for enrichment of ovarian cancer stem cells, mechanisms involved in drug resistance, and potential strategies for overcoming drug resistance, with associated potential controversies and pitfalls. We also review the potential relationship between epithelial-to-mesenchymal transition and cancer stem cells and how we can induce cancer cells to differentiate into benign stromal fibroblasts in response to certain chemotherapy drugs.

KW - Cancer stem cell

KW - Epithelial-mesenchymal transition

KW - High-grade ovarian serous cancer

UR - http://www.scopus.com/inward/record.url?scp=84885612943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885612943&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.05.001

DO - 10.1016/j.humpath.2013.05.001

M3 - Review article

C2 - 23850493

AN - SCOPUS:84885612943

SN - 0046-8177

VL - 44

SP - 2373

EP - 2384

JO - Human Pathology

JF - Human Pathology

IS - 11

ER -

Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this